E-LIB Suche - Ergebnisse für: Hierro, C

1

107P Unveiling mismatch repair deficiency (dMMR) and micros..:

Rincon, L. Notario ; Bergamino, M.A. ; Ochoa de Olza Amat, M....
ESMO Open. 8 (2023) 1 - p. 101917 , 2023

Link: https://doi.org/10.1016/..

2

Unveiling body composition as prognostic factor in metastat..:

Arribas, L. ; Llenas, A. ; González-Valencia, A....
Clinical Nutrition ESPEN. 58 (2023) - p. 625 , 2023

Link: https://doi.org/10.1016/..

3

67P Inflammation status and sarcopenia synergistically impa..:

Rincon, L. Notario ; Arribas, L. ; Esteve, A....
ESMO Open. 8 (2023) 1 - p. 101877 , 2023

Link: https://doi.org/10.1016/..

4

Safety, pharmacokinetics, and antitumor activity of the ant..:

Gazzah, A. ; Bedard, P.L. ; Hierro, C....
Annals of Oncology. 33 (2022) 4 - p. 416-425 , 2022

Link: https://doi.org/10.1016/..

5

Early-drug development in the era of immuno-oncology: are w..:

Ochoa de Olza, M.O. ; Oliva, M. ; Hierro, C....
Annals of Oncology. 30 (2019) 10 - p. 1670 , 2019

Link: https://doi.org/10.1093/..

6

Early interventions to detect potential drug–drug interacti..:

Azaro, A. ; Ghiglione, L. ; Valdivia, C....
European Journal of Cancer. 69 (2016) - p. S42 , 2016

Link: https://doi.org/10.1016/..

7

First-in-human phase I trial of the anti-CEACAM5 antibody–d..:

Gazzah, A. ; Stjepanovic, N. ; Ryu, M.H....
European Journal of Cancer. 69 (2016) - p. S14-S15 , 2016

Link: https://doi.org/10.1016/..

8

2399 Impact of KRAS mutations on clinical outcomes in advan..:

Sauri, T. ; Macarulla, T. ; Sanz-Garcia, E....
European Journal of Cancer. 51 (2015) - p. S470 , 2015

Link: https://doi.org/10.1016/..

9

3032A Activity and safety profile of lucitanib in patients ..:

Besse, B. ; Girard, N. ; Gazzah, A....
European Journal of Cancer. 51 (2015) - p. S607 , 2015

Link: https://doi.org/10.1016/..

10

Influence of Treatment Received in Long-Surviving Patients ..:

Taberna, M. ; Hierro, C. ; Vázquez, S....
International Journal of Radiation Oncology*Biology*Physics. 88 (2014) 2 - p. 531-532 , 2014

Link: https://doi.org/10.1016/..

11

386 PI3K and MEK inhibitor combination toxicities and relat..:

Azaro, A. ; Marino, D. ; Garrido-Castro, A....
European Journal of Cancer. 50 (2014) - p. 124 , 2014

Link: https://doi.org/10.1016/..

12

PO-081: Late Toxicity After Radical Treatment for Locally A..:

Taberna, M. ; Hierro, C. ; Diez, M....
Radiotherapy and Oncology. 106 (2013) - p. S34-S35 , 2013

Link: https://doi.org/10.1016/..

13

688 CELLULAR HETEROGENEITY IN THE EXPRESSION OF VITAMIN C T..:

Vaquero, J. ; Marin, J.J. Garcia ; Hierro, C....
Journal of Hepatology. 50 (2009) - p. S252 , 2009

Link: https://doi.org/10.1016/..

14

[308] PROTECTION AGAINST PHALLOIDIN HEPATOTOXICITY USING A ..:

Herraez, E. ; Macias, R.I. ; Vazquez-Tato, J....
Journal of Hepatology. 46 (2007) - p. S121-S122 , 2007

Link: https://doi.org/10.1016/..

15

Hodgkin's disease of middle ear and mastoid:

Solanellas, J. ; Esteban, F. ; Soldado, L....
The Journal of Laryngology & Otology. 110 (1996) 9 - p. 869-871 , 1996

Link: https://doi.org/10.1017/..